Wird geladen...

The Use of Chimeric Antigen Receptor T Cells in Patients With Non-Hodgkin Lymphoma

Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Adv Hematol Oncol
Hauptverfasser: Lulla, Premal D., Hill, LaQuisa C., Ramos, Carlos A., Heslop, Helen E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6469642/
https://ncbi.nlm.nih.gov/pubmed/29851933
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!